Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in Prescription Digital Therapeutics (PDTs), which are FDA-authorized software-based medical treatments. The company, which went public in 2021 via a business combination with Thimble Point Acquisition Corp., markets three products: reSET® for substance use disorder, reSET-O® for opioid use disorder, and Somryst® for chronic insomnia. Its intellectual property portfolio includes eleven exclusively owned patent families, two jointly owned patent families, and seven registered trademarks.